Summary Experiments have been carried out both in vitro and in vivo to examine the possibility of chemosensitization by misonidazole (MISO) at concentrations which are achievable in the clinic. Using multicellular tumour spheroids in vitro we found that a 16h pre-incubation with 100pgml-1 MISO under hypoxic conditions led to a considerable enhancement of sensitivity to melphalan (MEL) but not to CCNU. Pre-incubation for 16h under hypoxia alone also produced a degree of sensitization to MEL, but there was no effect of oxic pre-incubation with MISO. In vivo experiments using the KHT or RIF-l tumours in C3H mice were designed so that repeated administration of MISO maintained blood concentrations of around 100 gml-l for either 7h or 16h. For the 7h regime, cytotoxic drugs were administered at the 4h point. In most experiments the tumour response to MEL, cyclosphosphamide (CTX), chlorambucil or CCNU was no greater in mice receiving multiple MISO than in mice receiving multiple injections of a balanced salt solution. In the occasional experiment where there was an apparent increase in response, the effect was only small (dose modifying factor <1.5). For the 16 h regime the effect was studied of administering CTX (100mg kg -') at various times during the regime. There was a clear trend towards increased CTX response in mice receiving multiple MISO compared with controls. There was, however, no clear tendency for the effect to increase with length of MISO pre-exposure.
The electron-affinic agent, misonidazole (MISO), has been developed extensively as a radiation sensitizer of hypoxic cells (Adams, 1977 Stratford et al. (1980) that pre-incubation of Chinese hamster ovary (CHO) cells with MISO under hypoxic (but not oxic) conditions led to an enhanced sensitivity to nitrogen mustard, melphalan and cis-platinum, and this effect has been confirmed by Twentyman (1982) using growth delay in EMT6 tumour spheroids as the response endpoint. At the same time, a number of in vivo studies (Rose et al., 1980 , Clement et al., 1980 Tannock, 1980; Law et al., 1981; Twentyman, 1981; Martin et al., 1981; Siemann, 1981) have found that administration of MISO to mice at or around the time of cytotoxic drug administration can increase the anti-tumour effect of the cytotoxic drug.
In some of these studies a therapeutic gain is claimed in that the enhancement of the cytotoxic drug effect against the tumour is greater than that seen using a variety of normal tissue response endpoints.
These experimental investigations, both in vitro and in vivo, have, however, been carried out using concentrations or doses of MISO which are much higher than those normally attainable in the clinic. The in vitro studies of Stratford et al. (1980) and Twentyman (1982) both used a MISO concentration of 5mM (1000ugml-1) and a preincubation time of 2-5 h. The various in vivo experiments in the mouse have used MISO doses in the range 1.5-5mM kg-' (0.3-1 g kg-'). These would be expected to produce peak plasma concentrations of 1.5-5mM (300-1000ugml-1). In contrast the largest single dose of MISO which is usually given in clinical practice (3 gm-2) produces peak plasma concentrations of only 0.5-0.75mM (100-lSOugml-1) (for review see Workman, 1980) . The plasma half-life of MISO in humans, however, is 10-20 times longer than in the mouse (Workman, 1980) and therefore the relative -contributions to chemosensitization of peak plasma level and of exposure time is clearly a matter of importance.
In this paper we describe experiments designed to examine, both in vitro and in vivo the possibility of chemosensitization by clinically achievable concentrations of MISO. A study with similar objectives, recently reported by Brown & Hirst (1982) has produced encouraging in vivo data.
previously described (Twentyman, 1982) . Briefly, spheroids were grown in agar-coated flasks to a diameter of 250,u and then transferred to 100ml-spinner culture flasks for pre-incubation. In these experiments, pre-incubation at 37°C was either in the presence or absence of MISO (100 gml-') for 16 h under either oxic or hypoxic conditions. Hypoxia was achieved by passing nitrogen with 5% CO2 (<lopt 10-6 02; British Oxygen Co.) into the spinner vessels at a rate of 750-1000mlmin-'. After pre-incubation and rinsing, spheroids were exposed to graded concentrations of either melphalan (MEL) or CCNU for 1h in glass tubes with intermittent agitation. After this time, spheroids were again rinsed and transferred to individual wells on 96-well plastic multidishes. Successive measurements of spheroid diameter were made and growth curves constructed as previously described (Twentyman, 1982) .
Mice and tumours
The mice used in these studies were inbred C3H/He supplied by OLAC. Females were used in most experiments, but males were used occasionally. Mice entered experiments at age 12-16 weeks and weighed 20-28 g.
Tumours used were the KHT and RIF-1 sarcomas, both of which originated in C3H/Km mice at Stanford University, California, and which have been previously described (Kallman et al., 1967; Twentyman et al., 1980) . The methods used for tumour cell inoculation into the gastrocnemius muscle of the hind limb and subsequent measurement of tumour growth, including conversion of leg measurement to tumour weight, have also been described (Twentyman et al., 1979 (Workman, 12+ 1979) and reversed-phase high-performance liquid chromatography analysis (HPLC) (Workman et al., 1978) . Studies were carried out to confirm that tailvein blood concentrations were identical to those 10 obtained after cardiac puncture.
Two regimes of multiple MISO administration were used. In protocol A, administration continued up to 7 h, and the cytotoxic drugs were given 8 between the 3.5 h and 4 h injections. Tables III-IV. For CTX (Table III) the results are largely negative in that the growth delay for a given CTX dose is not significantly different in mice receiving MISO from that in mice receiving HBSS. In one experiment (i.e. Expt. B, 100mgkg-1) the difference is significant but the additional effect in the MISO treated group is less than that produced by increasing the CTX dose from 100 to 150mgkg-' in control mice. For MEL (Table IV) , the results are negative in 2/3 experiments. In experiment B, however, enhancement of MEL by a factor approaching 1.5 x was seen (i.e. MEL Figure 4 . It may be seen that at 2 times (i.e. 4 and 16 h) the values for CTX with MISO are significantly greater than those for CTX with HBSS. At the other times, the values are also greater but not significantly so. If all the groups are combined (i.e. irrespective of relative time of administration) the growth delay in mice receiving HBSS+CTX was 11.0+2.2 days and that in mice receiving MISO + CTX was 16.6 + 2.3 days. In the same experiment, we also looked at the effect of large single doses of MISO, given 30 min before CTX (100mgkg-1) and obtained growth delays of 16.6+2.5 days for CTX+5mMkg-1 of MISO and 15.9±4.9 days for CTX+2.5mMkg-1MISO 14.9 (13.9-16.0) 17.4 (16.4-18.3) combined Control i.e. 8.9 (8.1-9.6) 9.2 (8.1-10.6) 0 CTX
The growth delay is therefore 8.2 days for MISO pretreatment compared with 6.0 days for HBSS pretreatment.
In the same experiment, single dose MISO (5mMkg-1) increased the growth delay due to CTX 100 mgkg 1) from 6.0 days to 9.1 days, compared with 11.7 days for CTX (150mgkg-1) alone.
Discussion
The data from our in vitro experiments indicate that a 16-h exposure to 100gml-P1 of MISO under hypoxic conditions makes spheroids much more sensitive to growth delay induced by MEL. This is not true, however, for CCNU. These results are in agreement with our earlier study (Twentyman, 1982) where there were also differences in the ability of short hypoxic pre-exposure to MISO to sensitize --j f, )E spheroids to these two agents. We found that dose modifying factors were higher for MEL than for CCNU, and that there was a greater tendency with MEL than with CCNU for modification to depend upon the length of the pre-exposure period.
The results for our in vivo experiments using a 7-h MISO protocol are disappointing. In the majority of experiments no significant increase in drug response was caused by this MISO regime. Only in a single determination for MEL and a single determination for CHL are the data compatible with a dose modification of around 1.5. The bulk of the data suggest that dose modification by a factor > 1.2 is unlikely. This is clearly less than the dosemodifying factors which have been seen following large single dose MISO in the RIF-1 tumour with CTX (Twentyman, 1981; Law et al., 1981) or in the KHT tumour with CCNU (Siemann, 1981; Workman and Twentyman, 1982) . The results are contrary to those recently reported by Brown & Hirst (1982) who used a similar 7-h MISO protocol in the RIF-1 tumour and demonstrated clear sensitization to MEL and to CTX. Also, using different mouse tumour systems and 8h regimes of MISO exposure, positive chemosensitization to MEL and CTX has been found by Dr. N.J. McNally (personal communication) but an absence of effect is seen by Randhawa and Denekamp (personal communication) . This disparity of results may indicate that the 7-8h exposures are close to some critical level necessary for chemosensitization.
The 7-h regime with cytotoxic drug administration at 3.5-4h was originally chosen by Brown & Hirst (1982) as it closely resembles the clinical situation as used in radiotherapy. The peak plasma MISO concentration in man occurs at around 4 h after a single dose of 3 g m2 and does not fall much over the subsequent few hours. By giving the cytotoxic drug at this time we therefore had the advantage of a period of pre-exposure to MISO before cytotoxic drug administration, high levels at the time of drug administration, and continuing high levels during the active life of the drug. On the other hand, because of the relatively rapid fall in MISO levels in the mouse following the final MISO injection (t-1 h compared with 10 h in man), the total area under the blood MISO versus time curve (AUC) is still considerably less for the 7 h protocol in the mouse (3 mM . h) compared with that following 3 g m2 in man (8mM . h) (see Workman, 1980) . We therefore decided to extend the multiple injection regime in the mouse to 16 h (which does give an AUC of -8mM h) in order to closely equate the total MISO exposures.
Our data for CTX indicate that this 16h protocol produces more enhancement than the 7h protocol. However, there is a complete absence of timedependency in the effect, i.e. the time of CTX administration with respect to the 16 h MISO regime does not appear to be critical. This is not the result which would have been expected if the in vivo effect were due solely to a progressive depletion of thiols with time and may indicate that a number of contributing mechanisms are involved as found in vitro (Taylor et al., 1982) .
In conclusion, therefore, our in vitro studies indicate that clinically achievable MISO concentrations cause considerable sensitization of spheroids to MEL but not to CCNU. Our in vivo results are mostly negative for a 7 h MISO protocol, but positive with CTX for a 16 h regime.
